A Multi-Center, Long-Term, Open-Label Extension Study of [S,S]-Reboxetine (PNU-165442G) Administered Once Daily in Patients With Fibromyalgia.
Phase of Trial: Phase III
Latest Information Update: 21 Apr 2011
At a glance
- Drugs Esreboxetine (Primary)
- Indications Fibromyalgia
- Focus Adverse reactions
- Sponsors Pfizer
- 17 Mar 2009 Status changed from recruiting to discontinued, as reported by clinicaltrials.gov.
- 25 Feb 2009 Pfizer has decided to discontinue development of this drug, as reported in a media release.
- 03 Oct 2008 New trial record.